We are registered as an independent intermediary for medicines with the Dutch Ministry of Health
HR-positive, HER2-negative advanced or metastatic breast cancer epidermal gro
Mode of Action
Kinase inhibitor (targeted therapy)
EMA approved (EU); FDA approved (USA); TGA approved (AUS)
Who is ribociclib for?
Kisqali (ribociclib) is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer .
Complete information about Kisqali (ribociclib) dosage and administration can be found here: . The standard dosage is:
600 mg orally (three 200 mg tablets) taken once daily with or without food for 21 consecutive days followed by 7 days off treatment (one complete cycle consists of 28 days).
Dose interruption, reduction, and/or discontinuation may be required based on individual safety and tolerability.
Consult your treating doctor for personalised dosing.
What is ribociclib and how does it work?
Kisqali (ribociclib) is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer . Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Before a cell can divide, it has to go through four phases. The first phase is a growth phase (G1-phase), the second a synthesis phase (S-phase), the third another growth phase (G2-phase), and the last phase is where the cell divides (M-phase). Cancer cells divide exceedingly fast, passing through these 4 phases rapidly. Ribociclib blocks the progression from the first G1-phase, into the second S-phase. It does this by inhibiting the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6)— two proteins that are involved in entering the S-phase .
in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive HER2-negative advanced or metastatic breast cancer. The efficacy of Kisqali (ribociclib) was assessed in a randomised, double-blind, placebo-controlled, multicenter clinical study (MONALEESA-2) which compared ribociclib plus letrozole (N = 334) to placebo plus letrozole (N = 334) in a total of 668 postmenopausal women with HR-positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease . The median progression-free survival (PFS) (at the 2/01/2017 cutoff) was 25.3 months ribociclib plus letrozole group (95 % CI: 23.0, 30.3) and 16.0 months (95 % CI 13.4, 18.2) in the placebo group. The overall response rate was 54.5 % in the ribociclib plus letrozole group (95 % CI: 48.4 , 60.6) and 38.8 % (95 % CI 32.7, 44.9) in the placebo plus letrozole group . Most common adverse reactions (incidence ≥ 20%) are low levels of white blood cells, nausea, fatigue, diarrhea, alopecia, vomiting, constipation, headache, and back pain .
Buyer For EU individuals, VAT is 6% on medicines + 21% on shipping
Shipping Cost Estimate per order
VAT Tax can be claimed back by non-EU citizens on exiting the EU
Send this price estimate to your email address
Please complete the form, then try sending again.
*Once you provide us with the exact shipping address, the actual price may vary. After receiving the estimate, we may contact you to offer further assistance.
The more expensive medicines are patent-protected, and their prices are set by the pharmaceutical industry. We are constantly negotiating to get you best prices. As a social enterprise we only charge small fees to cover our operational costs.
Ordering with TheSocialMedwork is a safe and legal way to import a prescription medicine that has been approved in another country, but is not yet available where you live.
If you think that this medicine may be suitable for treating your condition, get in touch.
We'll answer any questions you might have and provide you with further information. Select the
Calculate Price tab to get a close estimate of the full cost of the medicine including delivery.
If you would like us to provide you with a precise quote we'll need to know the exact address of where you want us to send your medicine to.
2. Chat with your doctor
About whether this treatment might be suitable for you. In order to place an order with us, you’ll need to provide us with a prescription from your doctor who must be based in the same country where the medicine will be shipped to.
3. Place your order
Once you have your doctor's prescription you’re ready to place an order with us. Payment can be made by credit card, electronic bank transfer or Paypal.
As soon as we receive your payment we’ll process your order and your medicine will be shipped to you via a pharmacy.
Delivery time can vary from country to country but usually takes 1 to 3 weeks.
We'll send you a tracking number and keep you up to date on the status of your order.
Rest assured that we'll guide you through the entire process.
We'll let you know exactly what regulations need to be followed and the specific documentation you'll need to import the medicine into your country so that you get your treatment as quickly as possible. Ask us a question
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.
"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."
- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.
DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision.
Terms and Conditions